Ting-Chao Chou

Last updated
Ting-Chao Chou
周廷潮
Born (1938-09-09) 9 September 1938 (age 86)
Shinchiku, Taiwan under Japanese rule (modern Hsinchu, Taiwan)
Alma mater Kaohsiung Medical University (BS)
National Taiwan University (MS)
Yale University (PhD)
Scientific career
Fields Theoretical biology
Institutions Yale, Johns Hopkins, Cornell Memorial Sloan-Kettering Cancer Center

Ting-Chao Chou (born 1938 in Taiwan, Chinese name: 周廷潮) is a Chinese American theoretical biologist, pharmacologist, cancer researcher and inventor.

Contents

Biography

Chou was born in Changgangling Village, Hukou Township, Hsinchu County, Taiwan, on September 9, 1938, to Chao-Yun Chou and Sheng-Mei Chen.

Ancestry

His birthplace in Taiwan is Chou family's ancestral hall with a large insignia on the center "濓溪第:" (The Lianxi Place), "汝南堂" (Rue-nan Tarn), listing the family tree for 298 years. [1] "Chou (Zhou) Lianxi" is Chou Tun-i's posthumous name. Chou Tun-i (1017–1073; 周敦頤) was a Neo-Confucian philosopher and cosmologist of the Northern Song dynasty. His brief essay "On Praising Lotus Flower" (愛蓮說) was recited by many hundred millions of school children since it was selected in the standard high school textbook in both mainland China and Taiwan. T.C. Chou is an eighth-generation descendant of the Hakka Stream moving from Zhaozhou in Guangdong to Taiwan during the first year of Yongzheng Emperor of the Ching dynasty in 1723.

Education

Under Japan's rule of Taiwan 1895–1945, the Chou family established a private family school teaching Chinese characters and classics. His father was the teacher. After his father died, the widowed mother sent him to Hsin-Chu Normal School affiliated primary school with three-hour round-trip daily commute in the sixth grade. After the Taiwan Provincial Hsinchu High School, he entered Kaohsiung Medical University majoring in pharmaceutical sciences where he graduated summa cum laude. He was accepted by the Pharmacological Institute of National Taiwan University College of Medicine and received the master's degree under the mentorship of Chen-Yuan Lee, director of the institute, and dean of the Medical School. In 1965, he received a full scholarship from Yale University where he devoted to the mathematical aspects of quantitative biology. He received a Ph.D. degree with high honors. He did a postdoctoral fellowship at the Johns Hopkins University School of Medicine under Chairman of the Pharmacology Department, Paul Talalay, during 1970–1972.

In 1972 he joined the Laboratory of Pharmacology at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City as an assistant professor, affiliated to Cornell University Graduate School of Medical Sciences. He became a member and professor in 1988. After 40 years of service at MSKCC, he retired on June 1, 2013, from the directorship of Preclinical Pharmacology Core Laboratory, Molecular Pharmacology & Chemistry Program of MSKCC, and established the PD Science LLC in 2013 in Paramus, New Jersey, to promote MAL based biodynamics, pharmacodynamics, combination index, and bioinformatics [MAL-BD/PD/CI/BI] theory and application.

Publication and citation metrics

Peer-reviewed articles

T.C. Chou's 353 publications are listed in Web of Science. [2] The peer-reviewed articles have been cited 40,108 scientific papers published in over 1,469 bio-medical journals as of October 14, 2022. [3] [4] Mr. Chou has a H-index of 75 and i10-index of 285.

Other publications

Inventor/ co-inventor of 40 US patents. [5]

Theory, algorithm and definition

The Median-Effect Equation

The median-effect equation (MEE) of the mass-action law (MAL) was delivered by Chou in 1976 through the derivation of over 300 rate equations of enzyme dynamics, patten analysis, combination analysis, followed by mathematical induction and deduction. [6]

The relativity ratio of the fraction affected (fa) vs the fraction unaffected (fu) is equal to the dose (D) vs the median-effect dose (Dm) to the mth power, where Dm signifies potency and m signifies the sigmodicity (shape) of the dose-effect curve. [7] This median-effect equation, i.e. where fa + fu = 1, is the unified form for the Michaelis-Menten equation for enzyme substrate saturation, the Hill equation for ligand occupancy at high order, the Henderson-Hasselbalch equation for pH ionization, and the Scatchard equation for the receptor binding. Thus, the half-affected (Dm) is equivalent to half-saturated (Km), the half-occupied (K), half-ionized (pK) and half-bound and half-free (Kd). MEE is the simplest possible form for all the above equations in biochemistry and biophysics. The "median" is the common-link for single and multiple ligand interactions, and the universal reference point for the first-order and higher order dynamics. [8]

Median-effect plot

Also introduced by Chou in 1976 was the median-effect plot which is a plot of log (D) vs log [(fa)/(1-fa)] or log [(fa)/(fu)] yields a straight line with slope (m) and the x-intercept of log (Dm), where Dm equals to the anti-log of the x-intercept. This unique theory holds true for all dose-effect curves that follows the physico-chemical principle of the mass-action law, for all entities regardless of the first-order or higher-order dynamics, and regardless of unit or mechanism of actions. [7] [8] MEE is derived by system analysis using enzyme kinetics and mathematical inductions and deductions where hundreds of mechanism specific individual equations are reduced to a single general equation. [9] Both left and right sides of the MEE are dimensionless relativity ratio. When the m and Dm are determined, the full dose-effect curve is defined. Since the median-effect plot yields straight lines, the theoretical minimum of only two data points allow the drawing of the full dose-effect curve. This fundamental revelation defies the common held belief that two data points cannot draw a defined does-effect curve, since MAL algorithm adds two default points: does zero and Dm as the universal reference point. The main significance of MEE is the mediation that "Dose" and "Effect" or "Mass" and "Function" are interchangeable. The unified general MAL theory-based "top-down" approach [MAL-BD/PD/CI/BI] is opposite and yet the complimentary alternative to the traditional specific observations/statistics-based "bottom-up" approach for scientific research and development. [10] [9] [11]

Combination index theorem

The combination index (CI) concept was introduced by Chou T.C. and Talalay P. in 1984. [12] The derived combination index equation for two drugs is:

Where (Dx)1 is for (D)1 "alone" that inhibits a system x%, and (Dx)2 is for (D)2 "alone" that inhibits a system x% whereas in the numerator, (D)1 + (D)2, "in combination" also inhibit x%. Note that the denominators of the last two terms are the expression of MEE. The CI Value quantitatively defines synergism (CI<1), additive effect (CI=1) and antagonism (CI>1). [12] [10] [7]

Combination index Plot

Based on the above MEE and CI algorithms, a plot of CI values at different effect levels (fa's) can be determined by computer simulation (e.g. CompuSyn or CalcuSyn software, www. Combosyn.com, free download). [10] Entering a series of "dose (D) and effect (fa)" into computer for each drug alone and their combinations, the software will automatically simulate the CI values at different fa levels in seconds, based on the CI algorithm. This plot is also called the Fa-CI plot or the Chou-Talalay plot. [13] Depending on the experimental design, the combination mixtures can be at constant ratio or at non-constant ratios. The CI equations for three or more drug combinations have also been derived [7] and can be subjected to computer simulation. [10]

The CI theorem is developed for drugs (or effector entities) regardless of mechanism of actions, and regardless of dynamic orders and or the units of each drug in the combination. [8] The method has been applied in the combination of anti-cancer drugs, anti-HIV agents, drug-radiation, and traditional Chinese herbal medicines. [10] [9] [11] On March 16, 2016, the publisher/global website, Elsevier had a news release indicated "Chou & Talalay paper from 1984 makes history". [14]

Isobolograms

The idea of isobologram, i.e. the equi-effective curve at various concentrations or doses of two drugs, has been around for a century. However, only until 1984 the formal derivation of its equation in the general form was introduced by Chou and Talalay. The isobol equation is just a special case of the CI equation. [13] Thus automated computerized construction of either the classic isobologram (at constant ratio combinations) or the normalized isobologram (at non-constant ratio combination) can be performed in seconds using CompuSyn software. [10] In addition, the isobol method is now amendable for three or more drug combinations. Both Fa-CI plot and isobologram yield identical conclusion of synergism or antagonism. The Fa-CI plot is effect-oriented whereas isobol is dose-oriented. Both graphics can be considered two-sides of the same coin. However, Fa-CI plot is visually more convenient to use than isobologram since data point over crowding in isobologram at various effect levels can be avoided.

The Dose-Reduction Index (DRI)

The DRI is a measure of how many folds the dose of each drug in a synergistic combination may be reduced, at a given effect level, compared with the doses of each drug alone. The inverted terms in the CI equation, are the DRIs for the corresponding individual drugs in the combination. The reduced dose which will reduce toxicity at the increased effect would lead to beneficial clinical consequences. The algorithm and computerized simulation of the DRI plot at different effect levels (i.e. the Fa-DRI plot or Chou-Martin plot) has been available using the CompuSyn software. [10] DRI=1 indicates no dose reduction, whereas DRI>1 and <1 indicate favorable and unfavorable dose-reduction, respectively.

The Polygonogram

Taking the advantage of facile CI determination, a new simple graphic representation of three or more drug combinations has been introduced by T.C. Chou and J. Chou in 1998. [7] This method allows visual inspection of two-to-n drug combinations in the same circular frame which can be used to project the plausible semi-quantitative projection of what would happen at the higher numbers of drug combinations, form the low numbers of drug combinations. Using heavy red solid lines representing strong synergism and heavy blue broken lines representing strong antagonism, and thinner solid or broken lines for weaker interactions, a grading system can be established. It is easy to obtain the overall perspectives for planning the cocktail design of multiple drug combinations. The polygonogram graphics for five anticancer drugs with different mechanism of actions has been featured on the front-cover of May 2011 issue of Integrative Biology, published by the Royal Society of Chemistry, Cambridge UK. [8]

Applications of the theory

With the median-effect equation as the unified theory of the mass-action law and its combination index theorem for multiple effector interactions, these algorithms can be applied to virtually all aspects of quantitative biology and medical sciences as shown in over 1,469 different bio-medical journals. [3] [2] The conventional approach of dose-effect analysis in the past centuries has used numerous data points to draw the empirical dose-effect curve to best fit the available data by least square regression or other statistical means. This old approach is under the premises of assuming dose and effect relationships are random events. By contrast, the MEE theory is to use small number (usually 3–7) of data points to fit the mass-action law to yield its parameters (i.e. m, Dm and r), and to lineage all dose-effect curves with the automated median-effect plot. This led to "the theory of minimum of two data points" for easily defining the dose-effect curve with the m and Dm parameters. [7] [8] [15]

Econo-green bio-research

Minimum two dose data points theory

The revelation that all mass-action law based dose-effect curves can be transformed into straight lines with the median-effect plot leads to the theory that the theoretical minimum of two data points are required to define the entire dose-effect curve. In conjunction with the median-effect principle of the mass-action law, the referred "two data" points actually has the third data point at dose zero. In addition, the median-effect dose (Dm) is the fourth point which serves as the universal reference point and the common link to all dynamic orders. T.C. Chou has not contemplated to use only two data points for experimentation due to the fact that it requires highly accurate measurement and low variability for the high r values. [10] This mass-action theory leads to a green revolution in bio-medical research [7] [8] and effective and efficient drug development, as manifested in Chou's laboratory and elsewhere, in animal studies and in clinical trials. [16] [13]

Computer software and utilities

The major applications of the drug combinations are against the most dreadful diseases such as cancer and AIDS as indicated in the citation metrics. [16] Broad application includes drug-radiation combination, combination of insecticides and combinations of different modalities of effectors at different combination ratios, schedules and regimens. For single entity or drug, it calculate mass-action law parameters such as Dm values (IC50, ED50, LD50, ICx, EDx and LDx, etc.), m values (shape of dose-effect curves and dynamic orders) with computerized automation. [10]

Other applications [7] include: (i) Low-dose risk assessment of carcinogens, toxic substances and radiation, singly or in combination for environmental protection; (ii) Agricultural utilization of insecticides, and interaction of environmental factors; (iii) Topological analysis of receptor binding site for exclusivity and competitiveness; (iv) Calculation of Ki from IC50; (v) conservation of laboratory animals in research; and (vi) Efficient design of drug combination clinical trials using small number of patients, and thereby reducing time and cost. [10] [7] [8] [9] [11] [17]

Patents

U.S. Patents: Collaboration of pharmacologists with organic chemists and the employment of the mass-action law principle resulted in 40 U.S. patents, of which one is for the solo inventor. [5]

Some patents with promising utilities are selected for international patent applications. [5] These include synthetic microtubule targeting epothilone compounds against solid tumors and leukemias, such as Fludelone and Iso-Oxazole-Fludelone; [18] [19] [20] [21] [22] Immunosuppressants for organ transplantation, [17] such as Ardeemins and Ningalins, and synthetic cyto-protective Panaxytriols (inspired by Chinese/Korea ginseng) for reducing chemotherapy-induced toxicities such as body weight loss, peripheral neuropathy, alopecia, and death, and alleviation of radiation-induced toxicities. [23] [24]

Illustration of ancient philosophy

The algorithms of the median-effect equation and the combination index theorem of the physico-chemical principle of the mass-action law and their computer simulation offer the new interpretation/illustration of the ancient Chinese philosophy. This revelation of correspondence and complementarity have been presented or published at the following major national or international philosophical congress, conference, forum, or symposium: (i) American Philosophical Association East Annual Meeting, Baltimore, MD 12/28/2007; (ii) World Congress of Philosophy, Seoul, Korea 8/3/2008; (iii) Peking University School of Life Science and Department of Philosophy, Beijing, China 10/24/2008; [25] (iv) 16th International Conference of Chinese Philosophy sponsored by International Society of Chinese Philosophy, Taipei, Taiwan 7/8-15/2009; (v) 13th Yijing World Congress, Wuxi, China 6/14/2010; (vi) 7th International Forum on the Development of Traditional Chinese Medicine, Tianjin, China 9/21-23/2011; (vii) Bio-IT World Europe Bio Informatics 2011, Hanover, Germany 10/11-13/2011.

• Confucian Doctrine of the Mean (i-iii, vii): Median is the universal link

• Harmony and Daoism (v, vi, vii): Harmony is pure non-competitiveness

• Wuji er Taiji and Wu-Hsin (i, ii, v, vi): Material dynamics and equilibrium

• Fu Xi Ba Gua (ii, iii, v): Entity, time, space, vector, order and dynamics

Other publications

1. Book and other websites

2. The Unified Theory

3. Econo-Green Bio-Research and Computer Software

4. The 40 U.S. Patents

Related Research Articles

<span class="mw-page-title-main">ACE inhibitor</span> Class of medications used primarily to treat high blood pressure

Angiotensin-converting-enzyme inhibitors are a class of medication used primarily for the treatment of high blood pressure and heart failure. This class of medicine works by causing relaxation of blood vessels as well as a decrease in blood volume, which leads to lower blood pressure and decreased oxygen demand from the heart.

Synergy is an interaction or cooperation giving rise to a whole that is greater than the simple sum of its parts. The term synergy comes from the Attic Greek word συνεργία synergia from synergos, συνεργός, meaning "working together". Synergy is similar in concept to emergence.

<span class="mw-page-title-main">Paracetamol</span> Common medication for pain and fever

Paracetamol (acetaminophen) is a non-opioid analgesic and antipyretic agent used to treat fever and mild to moderate pain. It is a widely used over-the-counter medication. Common brand names include Tylenol and Panadol.

<span class="mw-page-title-main">Metformin</span> Medication used to treat diabetes

Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of Type 2 diabetes, particularly in people who are overweight. It is also used in the treatment of polycystic ovary syndrome, and is sometimes used as an off-label adjunct to lessen the risk of metabolic syndrome in people who take antipsychotics. It has also been shown to inhibit inflammation, and is not associated with weight gain. Metformin is taken orally.

<span class="mw-page-title-main">Atorvastatin</span> Cholesterol-lowering medication

Atorvastatin is a statin medication used to prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels. For the prevention of cardiovascular disease, statins are a first-line treatment. It is taken by mouth.

<span class="mw-page-title-main">Pharmacodynamics</span> Branch of pharmacology

Pharmacodynamics (PD) is the study of the biochemical and physiologic effects of drugs. The effects can include those manifested within animals, microorganisms, or combinations of organisms.

<span class="mw-page-title-main">Remifentanil</span> Synthetic opioid analgesic

Remifentanil, marketed under the brand name Ultiva is a potent, short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. The use of remifentanil has made possible the use of high-dose opioid and low-dose hypnotic anesthesia, due to synergism between remifentanil and various hypnotic drugs and volatile anesthetics.

<span class="mw-page-title-main">Nevirapine</span> Chemical compound

Nevirapine (NVP), sold under the brand name Viramune among others, is a medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medications. It may be used to prevent mother to child spread during birth but is not recommended following other exposures. It is taken by mouth.

<span class="mw-page-title-main">Doxylamine</span> First-generation antihistamine used as a short-term sedative and hypnotic (sleep aid)

Doxylamine is an antihistamine medication used to treat insomnia and allergies, and—in combination with pyridoxine (vitamin B6)—to treat morning sickness in pregnant women. It is available over-the-counter and is typically sold under such brand names as Equate or Unisom, among others; and it is used in nighttime cold medicines (e.g., NyQuil) and pain medications containing acetaminophen and/or codeine to help with sleep. The medication is delivered chemically by the salt doxylamine succinate and is taken by mouth. Doxylamine and other first-generation antihistamines are the most widely used sleep medications in the world. Typical side effects of doxylamine (at recommended doses) include dizziness, drowsiness, grogginess, and dry mouth, among others.

A polypill or single pill combination (SPC) is a type of drug combination consisting of a single drug product in pill form and thus combines multiple medications. The prefix "poly" means "multiple", referring to the multiplicity of distinct drugs in a given "pill". In precise usage, a pill is a polypill if it contains at least 4 drugs. An occasional synonym is combopill. A polypill commonly targets treatment or prevention of chronic conditions.

<span class="mw-page-title-main">Dextromethorphan</span> Cough suppressant, antidepressant, and dissociative drug

Dextromethorphan (DXM), sold under the trade name Robitussin among others, is a cough suppressant used in many cough and cold medicines. In 2022, the FDA approved the combination dextromethorphan/bupropion to serve as a rapid acting antidepressant in patients with major depressive disorder.

<span class="mw-page-title-main">Drospirenone</span> Medication drug

Drospirenone is a progestin and antiandrogen medication which is used in birth control pills to prevent pregnancy and in menopausal hormone therapy, among other uses. It is available both alone under the brand name Slynd and in combination with an estrogen under the brand name Yasmin among others. The medication is an analog of the drug spironolactone. Drospirenone is taken by mouth.

<span class="mw-page-title-main">Cycloserine</span> Tuberculosis medication

Cycloserine, sold under the brand name Seromycin, is a GABA transaminase inhibitor and an antibiotic, used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active drug resistant tuberculosis. It is given by mouth.

A combination drug or a fixed-dose combination (FDC) is a medicine that includes two or more active ingredients combined in a single dosage form. Terms like "combination drug" or "combination drug product" can be common shorthand for an FDC product, although the latter is more precise if in fact referring to a mass-produced product having a predetermined combination of drugs and respective dosages. And it should also be distinguished from the term "combination product" in medical contexts, which without further specification can refer to products that combine different types of medical products—such as device/drug combinations as opposed to drug/drug combinations. When a combination drug product is a "pill", then it may also be a kind of "polypill" or combopill.

<span class="mw-page-title-main">Pharmacokinetics</span> Branch of pharmacology

Pharmacokinetics, sometimes abbreviated as PK, is a branch of pharmacology dedicated to describing how the body affects a specific substance after administration. The substances of interest include any chemical xenobiotic such as pharmaceutical drugs, pesticides, food additives, cosmetics, etc. It attempts to analyze chemical metabolism and to discover the fate of a chemical from the moment that it is administered up to the point at which it is completely eliminated from the body. Pharmacokinetics is based on mathematical modeling that places great emphasis on the relationship between drug plasma concentration and the time elapsed since the drug's administration. Pharmacokinetics is the study of how an organism affects the drug, whereas pharmacodynamics (PD) is the study of how the drug affects the organism. Both together influence dosing, benefit, and adverse effects, as seen in PK/PD models.

In toxicodynamics and pharmacodynamics, Loewe additivity is one of several common reference models used for measuring the effects of drug combinations.

<span class="mw-page-title-main">Tesofensine</span> Chemical compound

Tesofensine (NS2330) is a serotonin–noradrenaline–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.

In the field of pharmacokinetics, the area under the curve (AUC) is the definite integral of the concentration of a drug in blood plasma as a function of time. In practice, the drug concentration is measured at certain discrete points in time and the trapezoidal rule is used to estimate AUC. In pharmacology, the area under the plot of plasma concentration of a drug versus time after dosage gives insight into the extent of exposure to a drug and its clearance rate from the body.

<span class="mw-page-title-main">Vibegron</span> Medication

Vibegron, sold under the brand name Gemtesa, is a medication for the treatment of overactive bladder. Vibegron is a selective beta-3 adrenergic receptor agonist.

Additive effect in pharmacology describes the situation when the combining effects of two drugs equal the sum of the effects of the two drugs acting independently. The concept of additive effect is derived from the concept of synergy. It was introduced by the scientists in pharmacology and biochemistry fields in the process of understanding the synergistic interaction between drugs and chemicals over the century.

References

  1. ↑ Chen, Stephen (11 March 2018). 2019 Taiwanese American Literature Collections. CreateSpace Independent Publishing Platform. ASIN   1986200973.
  2. 1 2 "Web of Science". www.webofscience.com. Retrieved 2022-10-13.
  3. 1 2 "Ting-Chao Chou". scholar.google.com. Retrieved 2022-10-13.
  4. ↑ "ORCID". orcid.org. Retrieved 2022-10-14.
  5. 1 2 3 "Ting-Chao Chou Inventions, Patents and Patent Applications - Justia Patents Search". patents.justia.com. Retrieved 2022-10-14.
  6. ↑ Chou, Ting-Chao (1976-07-07). "Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands". Journal of Theoretical Biology. 59 (2): 253–276. Bibcode:1976JThBi..59..253C. doi:10.1016/0022-5193(76)90169-7. PMID   957690.
  7. 1 2 3 4 5 6 7 8 9 Chou, Ting-Chao (2006-09-01). "Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies". Pharmacological Reviews. 58 (3): 621–681. doi:10.1124/pr.58.3.10. PMID   16968952. S2CID   7055257.
  8. 1 2 3 4 5 6 7 Chou, Ting-Chao (2011-03-14). "The mass-action law based algorithms for quantitative econo-green bio-research". Integrative Biology. 3 (5): 548–559. doi:10.1039/c0ib00130a. PMID   21403972.
  9. 1 2 3 4 Chou, Ting-Chao (May 2022). "MAL-pharmacodynamics theory based small-size experimental-design and analysis, in vitro, in animals and in clinical trial, with bioinformatics algorithm, for automated computer simulation to achieve quantitative/digital/indexed conclusions". The FASEB Journal. 36 (S1). doi: 10.1096/fasebj.2022.36.S1.R2801 . S2CID   248577717.
  10. 1 2 3 4 5 6 7 8 9 10 "Welcome to COMPUSYN". www.combosyn.com. Retrieved 2022-10-14.
  11. 1 2 3 Chou, Ting-Chao (May 2022). "Functional biodynamics theory and algorithms for inhibitor or activator effectors and their interactions, by computer simulation bioinformatics for translational medicine". The FASEB Journal. 36 (S1): fasebj.2022.36.S1.R3430. doi: 10.1096/fasebj.2022.36.S1.R3430 . S2CID   248592998.
  12. 1 2 Chou, Ting-Chao; Talalay, Paul (1984-01-01). "Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors". Advances in Enzyme Regulation. 22: 27–55. doi:10.1016/0065-2571(84)90007-4. PMID   6382953.
  13. 1 2 3 Chou, Ting-Chao (2010-01-13). "Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method". Cancer Research. 70 (2): 440–446. doi:10.1158/0008-5472.can-09-1947. PMID   20068163. S2CID   1324495.
  14. ↑ "Chou & Talalay paper from 1984 makes history - News - Advances in Enzyme Regulation - Journal - Elsevier". www.journals.elsevier.com. Retrieved 2022-10-14.
  15. ↑ Chou, Ting-Chao; Shapiro, Theresa A.; Fu, Jianing; Chou, Joseph H.; Ulrich-Merzenich, Gudrun S. (2019-12-01). "Computerized quantification of drugs synergism in animal studies or in clinical trials using only ten data points". Synergy. 9: 100049. doi:10.1016/j.synres.2019.100049. S2CID   190903318.
  16. 1 2 Chou, T.-C.; Motzer, R. J.; Tong, Y.; Bosl, G. J. (1994). "Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin Against Human Teratocarcinoma Cell Growth: a Rational Approach to Clinical Protocol Design". Journal of the National Cancer Institute. 86 (20): 1517–1524. doi:10.1093/jnci/86.20.1517. PMID   7932806 . Retrieved 2022-10-14.
  17. 1 2 "Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection". academic.oup.com. Retrieved 2022-10-14.
  18. ↑ Chou, Ting-Chao; Zhang, Xiu-Guo; Harris, Christina R.; Kuduk, Scott D.; Balog, Aaron; Savin, Kenneth A.; Bertino, Joseph R.; Danishefsky, Samuel J. (1998-12-22). "Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel". Proceedings of the National Academy of Sciences. 95 (26): 15798–15802. Bibcode:1998PNAS...9515798C. doi: 10.1073/pnas.95.26.15798 . PMC   28124 . PMID   9861050.
  19. ↑ Shan, Bei; Medina, Julio C.; Santha, Edit; Frankmoelle, Walter P.; Chou, Ting-C.; Learned, Robert M.; Narbut, Mathew R.; Stott, Dean; Wu, Pengguang; Jaen, Juan C.; Rosen, Terry; Timmermans, Pieter B. M. W. M.; Beckmann, Holger (1999-05-11). "Selective, covalent modification of β-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors". Proceedings of the National Academy of Sciences. 96 (10): 5686–5691. Bibcode:1999PNAS...96.5686S. doi: 10.1073/pnas.96.10.5686 . PMC   21921 . PMID   10318945.
  20. ↑ Chou, Ting-Chao; O'Connor, Owen A.; Tong, William P.; Guan, Yongbiao; Zhang, Zui-Guo; Stachel, Shawn J.; Lee, Chulbom; Danishefsky, Samuel J. (2001-07-03). "The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice". Proceedings of the National Academy of Sciences. 98 (14): 8113–8118. Bibcode:2001PNAS...98.8113C. doi: 10.1073/pnas.131153098 . PMC   35476 . PMID   11438750.
  21. ↑ "Therapeutic Cure against Human Tumor Xenografts in Nude Mice by a Microtubule Stabilization Agent, Fludelone, via Parenteral or Oral Route". aacrjournals.org. Retrieved 2022-10-14.
  22. ↑ Chou, Ting-Chao; Zhang, Xiuguo; Zhong, Zi-Yang; Li, Yong; Feng, Li; Eng, Sara; Myles, David R.; Johnson, Robert; Wu, Nian; Yin, Ye Ingrid; Wilson, Rebecca M.; Danishefsky, Samuel J. (2008-09-02). "Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones". Proceedings of the National Academy of Sciences. 105 (35): 13157–13162. Bibcode:2008PNAS..10513157C. doi: 10.1073/pnas.0804773105 . PMC   2529025 . PMID   18755900.
  23. ↑ "Abstract PO-062: Why drug and radiation combination synergism or antagonism can be quantitatively determined with the mass-action law based pharmacodynamics equation, algorithm and computer simulation". aacrjournals.org. Retrieved 2022-10-14.
  24. ↑ Chou, Ting-Chao; Dong, Huajin; Zhang, Xiuguo; Lei, Xiaoguang; Hartung, John; Zhang, Yandong; Lee, Jun Hee; Wilson, Rebecca M.; Danishefsky, Samuel J. (2011-08-23). "Multifaceted cytoprotection by synthetic polyacetylenes inspired by the ginseng-derived natural product, panaxytriol". Proceedings of the National Academy of Sciences. 108 (34): 14336–14341. Bibcode:2011PNAS..10814336C. doi: 10.1073/pnas.1111332108 . PMC   3161558 . PMID   21844359.
  25. ↑ "10月24日耶鲁大学博士周廷潮教授北大谈古论今". 2014-03-28. Archived from the original on 2014-03-28. Retrieved 2021-04-21.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.